SCOTUS ruling on confidential sales: lawyers comment
23-01-2019
SCOTUS likely to reverse Helsinn v Teva ruling, say lawyers
04-12-2018
stocknshares / iStockphoto.com
Companies that sell their inventions to third parties under confidential agreements may still end up invalidating their own patents based on the “on-sale” provision, the US Supreme Court said today.
If you have already subscribed please login.
If you have any technical issues please email tech support.
SCOTUS, US, AIA, patent invalidation, Helsinn Healthcare, Teva, generic version, proprietary information, confidential sales
